CTRI/2024/07/069984尚未招募Unknown
The Effect of Rifaximin and Standard Medical Therapy Vs Standard Medical Therapy Alone on Myosteatosis in Patients with Decompensated Cirrhosis- A Randomised Controlled Trial - NI
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Patients of decompensated cirrhosis of any etiology
- •2) Evidence of myosteatosis on CT
排除标准
- •1. Patients with CTP score more than 10.
- •2. Patient with acute on chronic liver failure (ACLF)
- •3. Patients with active malignancy, hepatocellular carcinoma, and end-stage renal
- •4. Patients having prior study enrolment or enrolment in another conflicting
- •5. Patients, not willing to participate in the study.
- •6. Individuals who have engaged in other clinical trials within the preceding 3 months.
- •7. Patients who have active evidence of infection.
- •8. Patients who had acute organic brain disease in the past 6 months.
- •9. Individuals experiencing severe hemodynamic instability, significant heart disease,
- •pronounced bradycardia, or resting tachycardia.
- •10. Renal failure patients (creatinine clearance rate 60 mL/min/1.73 m2).
- •11. Patients with severe cognitive impairment, overt hepatic encephalopathy, or patients
- •who had a physical disability.
- •12. Patients with HIV
- •13. Pregnancy
- •14. Post liver transplant patients
- •15. Exposure to Rifaximin in the previous 12 weeks
- •16. Known hypersensitivity to Rifaximin
研究者
相似试验
尚未招募
3 期
to see the effect of Standard medical therapy along with rifaximin intervention vs. standard medical therapy alone on muscle wasting in patients with cirrhosis : A PILOT Randomized Controlled TrialCTRI/2023/04/051474AIIMS
尚未招募
不适用
Standard medical therapy plus rifaximin vs. standard medical therapy alone for the management of sarcopenia in patients with cirrhosisCTRI/2022/03/040923AIIMS New Delhi
已完成
不适用
A study to compare effects of Tablet Rifaximin alone and in combination with Tablet Norfloxacin for prevention of re-occuring bacterial infection of abdominal fluid and brain function abnormality due to liver disease.CTRI/2021/09/036321Pt BD Sharma PGIMS Rohtak49
已完成
3 期
The effect of rifaximin in different doses on symptoms and quality of life improvement in Iranian patients with diarrhea-predominant irritable bowel syndromeIrritable bowel syndrome with diarrheaIRCT20141201020178N11Iran University of Medical Sciences200
已完成
不适用
ROLE OF RIFAXIMIN ON FRAILTY (MUSCLE WEAKNESS) IN DECOMPENSATED CIRRHOSIS (CHRONIC LIVER DISEASE)CTRI/2023/01/048824PGIMER100